Every week, another glaucoma patient sits across from me and mentions they have started taking NMN (nicotinamide mononucleotide). They heard about it from a podcast. Or a friend. Or a longevity influencer whose advice they trust.
They are doing everything they can to protect their vision — and NMN, they have been told, is one of the most powerful tools available for cellular health and healthy ageing.
The trouble is that nobody is telling them what the science shows about NMN specifically in glaucoma. And it is not a comfortable story.

Why NMN Has Become So Popular
The names behind NMN’s rise are not fringe figures.
Harvard professor Dr David Sinclair — one of the world’s most cited ageing researchers and author of Lifespan — takes one gram of NMN every morning and has discussed it across dozens of major podcasts and interviews. Neuroscientist Dr Andrew Huberman has also publicly advocated for it. When researchers of this calibre endorse a supplement, people pay attention.
The science behind the appeal is real. As we age, levels of a molecule called NAD+ decline throughout the body. NAD+ sits at the heart of how cells produce energy, repair DNA, and keep themselves running.

NMN is a substance the body can convert into NAD+ — and the logic of taking it to slow the ageing process and support cellular health is sound, for the general population.
Which is exactly why so many glaucoma patients have started taking it.
The problem is that glaucoma is not a general ageing condition. It has a specific pattern of cellular dysfunction in the optic nerve — and in that specific context, the behaviour of NMN is very different from what the anti-ageing research suggests.
What Is Actually Happening Inside the Optic Nerve
To understand why NMN is a concern in glaucoma, you need to understand something about how glaucoma damages the optic nerve that most patients are never told.
Think of the mitochondria in your cells as batteries. The cells of the optic nerve — called retinal ganglion cells — are among the most energy-hungry in the entire body. They need to fire electrical signals continuously, carrying everything you see from your retina to your brain. Their batteries need to be constantly charged. The charge itself is NAD+.
In glaucoma, those batteries run flat. NAD+ levels fall with age — by up to 50% across a lifetime — and fall faster still under the stress of glaucoma. When the batteries cannot hold their charge, the cells become vulnerable. And eventually, they die.
Both NMN and nicotinamide, a form of vitamin B3, are substances the body can use to help recharge those batteries. The logic behind taking either one seems identical: if the batteries are flat, give them something to boost the charge. But what happens inside the glaucomatous eye when you take each one could not be more different.

The Hidden Risk of NMN in Glaucoma
Here is what the longevity community is not discussing.
In glaucoma, elevated eye pressure does something specific and damaging: it causes NMN to accumulate inside the optic nerve while NAD+ levels simultaneously fall. The batteries are flat — and the raw materials meant to recharge them are piling up unused.
The result is a dangerous imbalance: too much NMN, not enough NAD+.
Research has shown that when this imbalance tips too far, it activates a self-destruct programme in the nerve fibres of the optic nerve — triggering a process in which the axons actively destroy themselves. A rise in NMN following nerve injury has been shown to directly drive this degeneration.
When a glaucoma patient supplements with NMN from outside the body, they risk worsening exactly that imbalance — more NMN flooding in, without a corresponding rise in NAD+, pushing the ratio further in the wrong direction.
In a disease where the nerve fibres of the optic nerve are already under threat, this is not a theoretical concern. It is a plausible mechanism for accelerating the very damage they are trying to prevent.
Why Nicotinamide Is Different
Nicotinamide also helps the body produce NAD+. But it behaves very differently to NMN inside the glaucomatous eye.
Research in experimental glaucoma has shown that nicotinamide treatment actually normalises the NMN:NAD+ ratio in eyes with elevated pressure — the opposite of what supplemental NMN does. Rather than adding to the dangerous imbalance, nicotinamide corrects it. The batteries get recharged without triggering the self-destruct signal.
There is a second advantage. Nicotinamide crosses the blood-brain barrier efficiently and has been shown to be more effective than NMN (or NR — nicotinamide riboside — another popular NAD+ supplement) at raising NAD+ levels specifically inside retinal ganglion cells.
Getting the charge to the right batteries, in the right cells, is what matters. And nicotinamide does this better than any of its alternatives.
This is why nicotinamide — not NMN, not NR — is the compound being studied in every major glaucoma neuroprotection trial. That is not an accident. The mechanism is specific, and it specifically favours nicotinamide.
What This Means If You Are Taking NMN
No clinical trial has yet proven that NMN causes harm in people with glaucoma. Most of the evidence is from laboratory and animal studies.
But the science behind the concern is solid, the risk is biologically plausible, and — crucially — there is a better option available (nicotinamide) that is supported by both clinical evidence and the right mechanism for the glaucomatous optic nerve.
So if you have glaucoma and are currently taking NMN, or considering it, bring this article to your next appointment and have the conversation with your ophthalmologist or GP.
The longevity industry is not designed to give advice tailored to the specific vulnerabilities of the glaucomatous optic nerve. That is not a criticism — it simply reflects the fact that general cellular health and disease-specific neuroprotection are different problems, requiring different solutions.
This is precisely why I developed the NP-10 System — a framework for addressing the ten biological mechanisms that drive glaucoma damage using interventions that are supported by glaucoma-specific research. The supplement choices within that framework are not arbitrary. They are specific. And in glaucoma, specificity matters.

If you want to stop second-guessing your supplement choices and start building a glaucoma care plan you can actually trust — follow me and explore the rest of this website.
This information is for educational purposes only and does not replace advice from your treating specialist. Always discuss any supplement or lifestyle changes with your ophthalmologist or GP before making any changes to your treatment.
Dr Brian Ang is a glaucoma surgeon in Melbourne, the author of Proactive Glaucoma Care, and the co-founder of Nutravision — which contains nicotinamide as one of its ingredients.